# SATELLITE Study (feaSibility sAfeTy Efficacy dostarLimab earLy-stage defIcient endomeTrial cancEr)

> **NCT06278857** · PHASE2 · RECRUITING · sponsor: **Queensland Centre for Gynaecological Cancer** · enrollment: 10 (estimated)

## Conditions studied

- Endometrial Cancer Stage I
- Mmr Deficiency
- Endometrioid Endometrial Adenocarcinoma
- Immune-related Adverse Event

## Interventions

- **DRUG:** Dostarlimab-Gxly 50 MG/1 ML Intravenous Solution [JEMPERLI]

## Key facts

- **NCT ID:** NCT06278857
- **Lead sponsor:** Queensland Centre for Gynaecological Cancer
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-01
- **Primary completion:** 2026-06-30
- **Final completion:** 2028-06-30
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2024-12-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06278857

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06278857, "SATELLITE Study (feaSibility sAfeTy Efficacy dostarLimab earLy-stage defIcient endomeTrial cancEr)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06278857. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*